Sanofi Receives US Approval for Groundbreaking Treatment
Sanofi’s Wayrilz has secured approval in the US as the first BTK inhibitor for immune thrombocytopenia. This approval underscores the company’s commitment to advancing medical solutions.
Wayrilz Approval Details
- The US approval is for the treatment of immune thrombocytopenia, a condition characterized by low platelet count.
- Wayrilz is a BTK inhibitor, a class of medications that target the Bruton’s tyrosine kinase enzyme.
Financial Performance
Sanofi’s stock price has fluctuated within a 52-week range of 76.78 EUR to 110.88 EUR. The current price of 84.49 EUR indicates a decline from the 52-week high.
Key Financial Metrics
- 52-week high: 110.88 EUR
- 52-week low: 76.78 EUR
- Current stock price: 84.49 EUR
- Price-to-earnings ratio: 17.084
- Price-to-book ratio: 1.47
